(c) 2024 PillSync.com

atorvastatin calcium 40 mg

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥190 mg/dL or b. LDL-C remains ≥160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).

directrx


3 years ago OVAL WHITE ATO 40 atorvastatin calcium 40 mg

OVAL WHITE ATO 40

3 years ago OVAL WHITE ATO 40 atorvastatin calcium 40 mg

ATO 40 OVAL WHITE



ATORVASTATIN CALCIUM tablets USP, 10 mg are white to off-white, film-coated, oval shaped tablets "ATO" debossed on one side and "10" on other side. NDC 75834-255-90 bottles of 90 NDC 75834-255-01 bottles of 1000 NDC 75834-255-05 bottles of 5000 NDC 75834-255-50 bottles of 500

ATORVASTATIN CALCIUM tablets USP, 20 mg are white to off-white, film-coated, oval shaped tablets "ATO" debossed on one side and "20" on other side. NDC 75834-256-90 bottles of 90 NDC 75834-256-01 bottles of 1000 NDC 75834-256-05 bottles of 5000 NDC 75834-256-50 bottles of 500

ATORVASTATIN CALCIUM tablets USP, 40 mg are white to off-white, film-coated, oval shaped tablets "ATO" debossed on one side and "40" on other side. NDC 75834-257-90 bottles of 90 NDC 75834-257-50 bottles of 500 NDC 75834-257-25 bottles of 2500 NDC 75834-257-01 bottles of 1000

ATORVASTATIN CALCIUM tablets USP, 80 mg are white to off-white, film-coated, oval shaped tablets "ATO" debossed on one side and "80" on other side. NDC 75834-258-90 bottles of 90 NDC 75834-258-50 bottles of 500 NDC 75834-258-02 bottles of 2000 NDC 75834-258-01 bottles of 1000 Storage Store at controlled room temperature 20°C - 25°C (68°F - 77°F) [see USP].


More pills like OVAL ATO 40












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site